Cogent Biosciences, Inc.
COGT · Nasdaq · United States
Share price · COGT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when COGT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026-7.1%
Nothing announced by COGT that day or the session before.
- 10 Nov 2026-5.7%
Nothing announced by COGT that day or the session before.
- 6 Nov 2026+7.0%
- 11 Aug 2026-6.8%
- 4 Aug 2026+10.2%
Nothing announced by COGT that day or the session before.
- 1 Apr 2026-8.4%
Nothing announced by COGT that day or the session before.
- 23 Mar 2026+6.1%
Nothing announced by COGT that day or the session before.
Share of unusual movement by asset
For each asset, the share of COGT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | KITSmall molecule | Systemic MastocytosisGastrointestinal Stromal Tumor | |
| Phase 1 | ERBB2 (HER2), including genetic alterations and wild-type overexpressionSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | PI3Kα H1047R (mutant-selective inhibitor)Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(9)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $75M | $218M+ $574M short-term inv. | $111M-$81M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $71M | $182M+ $611M short-term inv. | $96M-$77M operating cash flow | report ↗ |
| 2026-Q1 | — | $75M | $242M+ $625M short-term inv. | $97M-$87M operating cash flow | report ↗ |
| 2025-Q3 | — | $69M | $126M+ $266M short-term inv. | $81M-$64M operating cash flow | report ↗ |
| 2025-Q2 | — | $62M | $128M+ $110M short-term inv. | $74M-$55M operating cash flow | report ↗ |
| 2025-Q1 | — | $63M | $126M+ $120M short-term inv. | $72M-$67M operating cash flow | report ↗ |
| 2024-Q3 | — | $64M | $97M+ $238M short-term inv. | $71M-$52M operating cash flow | report ↗ |
| 2024-Q2 | — | $54M | $88M+ $275M short-term inv. | $59M-$43M operating cash flow | report ↗ |
| 2024-Q1 | — | $53M | $216M+ $220M short-term inv. | $58M-$53M operating cash flow | report ↗ |
| 2023-Q3 | — | $50M | $87M+ $192M short-term inv. | $55M-$38M operating cash flow | report ↗ |
| 2023-Q2 | — | $39M | $214M+ $115M short-term inv. | $44M-$32M operating cash flow | report ↗ |
| 2023-Q1 | — | $36M | $162M+ $60M short-term inv. | $39M-$40M operating cash flow | report ↗ |
| 2022-Q3 | — | $30M | $142M+ $149M short-term inv. | $35M-$34M operating cash flow | report ↗ |
| 2022-Q2 | — | $29M | $327M | $35M-$26M operating cash flow | report ↗ |
| 2022-Q1 | — | $25M | $192M | $31M-$28M operating cash flow | report ↗ |
| 2021-Q3 | — | $15M | $204M | $19M-$14M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $270M | $312M+ $589M short-term inv. | $82M-$264M operating cash flow | report ↗ |
For the full year 2025, Cogent Biosciences did not disclose revenue. Research and development expenses totaled $269.78M, up 16.0% YoY from $232.66M, while the company reported a net loss of $328.94M. It ended the year with cash, cash equivalents and marketable securities of $900.8M.
Cogent guided to cash sufficient to fund operations into 2028 and expects to launch bezuclastinib in the second half of 2026 pending FDA approval. The SUMMIT NDA for NonAdvSM was submitted in December 2025, the APEX NDA for AdvSM remains on track for the first half of 2026, and the PEAK NDA for second-line GIST is being completed under Real-Time Oncology Review by April 2026. The company also highlighted six SUMMIT abstracts accepted for the 2026 AAAAI meeting, positive topline results from the PEAK and APEX trials, and approximately $546.8M in net proceeds from concurrent public offerings completed in November 2025.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $233M | $98M+ $189M short-term inv. | $64M-$208M operating cash flow | report ↗ |
| 2023-FY | — | $174M | $53M+ $212M short-term inv. | $48M-$154M operating cash flow | report ↗ |
| 2022-FY | — | $122M | $141M+ $119M short-term inv. | $35M-$119M operating cash flow | report ↗ |
| 2021-FY | — | $56M | $221M+ $0 short-term inv. | $18M-$59M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 8 sales ($383.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | Ferrante Karen Jean · director | Award / grant (derivative) | 759 | — | — | Form 4 |
| 2026-08-27 | Morris Arlene · director | Option exercise | 41,927 | $5.64 | $236K | Form 4 |
| 2026-08-27 | Morris Arlene · director | Option exercise | 3,583 | $2.52 | $9K | Form 4 |
| 2026-08-27 | Morris Arlene · director | Open-market sale | 42,349 | $37.09 | $1.6M | Form 4 |
| 2026-08-27 | Morris Arlene · director | Open-market sale | 3,161 | $37.54 | $119K | Form 4 |
| 2026-08-27 | Morris Arlene · director | Option exercise (derivative) | 41,927 | — | — | Form 4 |
| 2026-08-27 | Morris Arlene · director | Option exercise (derivative) | 3,583 | — | — | Form 4 |
| 2026-07-01 | Ferrante Karen Jean · director | Award / grant (derivative) | 627 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 303 reporting institutions held 186.3M shares ($6.9B, 107.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 23,122,748 | $890.0M |
| 2 | BlackRock, Inc. | 16,045,014 | $617.6M |
| 3 | DEERFIELD MANAGEMENT COMPANY, L.P. | 9,043,903 | $348.1M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,333,333 | $282.3M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 6,894,959 | $265.4M |
| 6 | JANUS HENDERSON GROUP PLC | 5,965,125 | $229.6M |
| 7 | STATE STREET CORP | 5,663,543 | $218.0M |
| 8 | Fairmount Funds Management LLC | 5,503,418 | $211.8M |
| 9 | RTW INVESTMENTS, LP | 5,458,675 | $210.1M |
| 10 | TCG Crossover Management, LLC | 4,946,894 | $190.4M |
| 11 | GOLDMAN SACHS GROUP INC | 4,434,054 | $170.7M |
| 12 | Kynam Capital Management, LP | 4,037,331 | $155.4M |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 3,699,519 | $142.4M |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 3,578,622 | $137.7M |
| 15 | Commodore Capital LP | 2,888,007 | $111.2M |